Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.31), $0.22 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• UBS Upgrades FTC Solar Inc. (FTCI) to Buy
• UBS Downgrades Anhui Jianghuai Automobile Group Co Ltd (600418:CH) to Sell
• UBS Upgrades Waste Connections Inc. (WCN) to Buy